Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII.

We investigated the mechanisms responsible for severe factor VII (FVII) deficiency in homozygous Italian patients with either Gly97Cys or Gln100Arg mutations in the second epidermal growth factor domain of FVII. Transient expression of complementary DNA coding for the mutations in COS-1 cells showed impaired secretion of the mutant molecules. Using stably transfected Chinese hamster ovary (CHO) cells, we performed pulse-chase labeling studies, immunohistochemistry, and experiments with inhibitors of protein degradation, showing that FVII-Cys97 did not accumulate intracellularly but was degraded in a pre-Golgi, nonlysosomal compartment by a cysteine protease. In stably transfected CHO cells expressing FVII-Arg100, the level of intracellular FVII was not increased by several inhibitors of protein degradation, but FVII-Arg100 was retained in the endoplasmic reticulum for a longer period of time than wild-type FVII. FVII-Arg100 had a lower apparent molecular weight than did wild-type FVII under nondenaturing conditions, which is attributable to misfolding due to abnormal disulfide bond formation.

[1]  A. Arbini,et al.  Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation , 1999, British journal of haematology.

[2]  D. Banner,et al.  Coagulation Factor VII Gln100 → Arg , 1998, The Journal of Biological Chemistry.

[3]  A. Arbini,et al.  The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[4]  P. Mannucci,et al.  Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  D. Cooper,et al.  Inherited Factor VII Deficiency: Molecular Genetics and Pathophysiology , 1997, Thrombosis and Haemostasis.

[6]  R. Stephens,et al.  A peptide sequence from the EGF-2 like domain of FVII inhibits TF-dependent FX activation. , 1997, Thrombosis research.

[7]  R. Kaufman,et al.  Factor VIII C2 Domain Missense Mutations Exhibit Defective Trafficking of Biologically Functional Proteins* , 1996, The Journal of Biological Chemistry.

[8]  S. Ōmura,et al.  Degradation of a Mutant Secretory Protein, α1-Antitrypsin Z, in the Endoplasmic Reticulum Requires Proteasome Activity* , 1996, The Journal of Biological Chemistry.

[9]  A. Arbini,et al.  A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule. , 1996, Blood.

[10]  S. Humphries,et al.  Low Plasma Levels of Factor Vile and Antigen Are More Strongly Associated with the 10 Base Pair Promoter (-323) Insertion than the Glutamine 353 Variant , 1996, Thrombosis and Haemostasis.

[11]  David W. Banner,et al.  The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor , 1996, Nature.

[12]  J. Auwerx,et al.  The Mutation Gly Glu in Human Lipoprotein Lipase Produces a Missorted Protein That Is Diverted to Lysosomes (*) , 1996, The Journal of Biological Chemistry.

[13]  G C Overton,et al.  Functional Characterization of the Human Factor VII 5′-Flanking Region (*) , 1996, The Journal of Biological Chemistry.

[14]  J. Riordan,et al.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.

[15]  S Grinstein,et al.  Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.

[16]  A. Arbini,et al.  Molecular analysis of Polish patients with factor VII deficiency. , 1994, Blood.

[17]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[18]  Mark C. Field,et al.  Retention and degradation of proteins containing an uncleaved glycosylphosphatidylinositol signal. , 1994, The Journal of biological chemistry.

[19]  D. Cooper,et al.  Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII. , 1993, Human molecular genetics.

[20]  R. Kaufman,et al.  Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. , 1991, Nucleic acids research.

[21]  W. Kisiel,et al.  Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine. , 1991, The Journal of biological chemistry.

[22]  H. ten Cate,et al.  Factor IX is activated in vivo by the tissue factor mechanism. , 1990, Blood.

[23]  W. Kisiel,et al.  Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. , 1989, The Journal of biological chemistry.

[24]  Y. Ikehara,et al.  Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. , 1988, The Journal of biological chemistry.

[25]  L. Thim,et al.  Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. , 1988, Biochemistry.

[26]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[27]  J. Brandt,et al.  Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. , 1985, Blood.

[28]  J. Miletich,et al.  Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII. , 1985, The Journal of clinical investigation.

[29]  A. Tarentino,et al.  Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F. , 1985, Biochemistry.

[30]  K. Kurachi,et al.  Characterization of a cDNA coding for human factor VII. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Fair.  Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. , 1983, Blood.

[32]  M. Ragni,et al.  Factor VII deficiency , 1981, American journal of hematology.

[33]  L. Chasin,et al.  Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Osterud,et al.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[35]  L. Kunkel,et al.  Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F. Maley,et al.  Purification and properties of an endo-beta-N-acetylglucosaminidase from Streptomyces griseus. , 1974, The Journal of biological chemistry.